EPO and Alzheimer disease: EPO-SLN prevented Aβ1-42-induced impairment of spatial recognition memory in AD model. Additionally, the EPO-SLN showed the anti-oxidant properties, prevented the Aβ plaque deposition, and decreased the ADP/ATP ratio, suggesting the suitability of the developed system for AD treatment.